Success Metrics

Clinical Success Rate
92.5%

Based on 99 completed trials

Completion Rate
93%(99/107)
Active Trials
16(11%)
Results Posted
41%(41 trials)
Terminated
8(5%)

Phase Distribution

Ph early_phase_1
6
4%
Ph phase_1
13
9%
Ph phase_2
35
23%
Ph phase_4
52
35%
Ph not_applicable
17
11%
Ph phase_3
22
15%

Phase Distribution

19

Early Stage

35

Mid Stage

74

Late Stage

Phase Distribution145 total trials
Early Phase 1First-in-human
6(4.1%)
Phase 1Safety & dosage
13(9.0%)
Phase 2Efficacy & side effects
35(24.1%)
Phase 3Large-scale testing
22(15.2%)
Phase 4Post-market surveillance
52(35.9%)
N/ANon-phased studies
17(11.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

99 of 110 finished

Non-Completion Rate

10.0%

11 ended early

Currently Active

16

trials recruiting

Total Trials

150

all time

Status Distribution
Active(18)
Completed(99)
Terminated(11)
Other(22)

Detailed Status

Completed99
unknown21
Recruiting11
Terminated8
Active, not recruiting5
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
150
Active
16
Success Rate
92.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (4.1%)
Phase 113 (9.0%)
Phase 235 (24.1%)
Phase 322 (15.2%)
Phase 452 (35.9%)
N/A17 (11.7%)

Trials by Status

terminated85%
active_not_recruiting53%
recruiting117%
suspended11%
withdrawn32%
not_yet_recruiting21%
completed9966%
unknown2114%

Recent Activity

Clinical Trials (150)

Showing 20 of 150 trialsScroll for more
NCT05663866Phase 2

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Active Not Recruiting
NCT07101445Phase 4

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Recruiting
NCT02104674Phase 3

A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma

Completed
NCT07685886Phase 4

MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

Not Yet Recruiting
NCT05498116Phase 4

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

Recruiting
NCT05922761Phase 2

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Recruiting
NCT04572256Early Phase 1

MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

Recruiting
NCT07409714Early Phase 1

SMART 2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults With Type 2 Diabetes

Not Yet Recruiting
NCT02793375Phase 3

Does Montelukast Decrease Post Adenotonsillectomy Pain in Children

Completed
NCT04268498Phase 2

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Active Not Recruiting
NCT06113640Phase 2

Montelukast in Parkinson Disease

Recruiting
NCT05896228Phase 2

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
NCT05959889Not Applicable

Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer

Completed
NCT06356571Phase 2

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting
NCT04294641Phase 2

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Completed
NCT07320625Phase 3

Efficacy of Montelukast on STEMl Patients

Recruiting
NCT05704049Phase 2

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Active Not Recruiting
NCT04885530Phase 3

ACTIV-6: COVID-19 Study of Repurposed Medications

Completed
NCT05405166Phase 3

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Active Not Recruiting
NCT06019728Phase 4

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Completed

Drug Details

Intervention Type
DRUG
Total Trials
150